Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study.

Behrend H, Lengnick H, Zdravkovic V, Ladurner A, Rudin D, Erschbamer M, Joerger M, Kuster M.

Knee Surg Sports Traumatol Arthrosc. 2018 Jun 28. doi: 10.1007/s00167-018-5030-3. [Epub ahead of print]

PMID:
29955932
2.

Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy.

Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Won Kim T, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M.

Clin Pharmacol Ther. 2018 Jun 20. doi: 10.1002/cpt.1124. [Epub ahead of print] Review. No abstract available.

PMID:
29923599
3.

Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer.

Siano M, Jarisch N, Joerger M, Espeli V.

Anticancer Res. 2018 Jun;38(6):3725-3729. doi: 10.21873/anticanres.12652.

PMID:
29848734
4.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R.

Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13.

PMID:
29660598
5.

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.

Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé VO, Van Calster B, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2312-2318. doi: 10.1158/1078-0432.CCR-17-3028. Epub 2018 Feb 19.

PMID:
29459457
6.

Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM).

Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, Jog S, Baburina I, Miller MC, Salamone SJ.

Ther Drug Monit. 2017 Dec;39(6):617-624. doi: 10.1097/FTD.0000000000000446.

PMID:
28937535
7.

Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.

Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen ZP.

J Pharmacol Exp Ther. 2017 Aug;362(2):347-358. doi: 10.1124/jpet.117.240309. Epub 2017 Jun 9.

PMID:
28600397
8.

Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.

Klopp-Schulze L, Joerger M, Wicha SG, Ter Heine R, Csajka C, Parra-Guillen ZP, Kloft C.

Clin Pharmacokinet. 2018 Feb;57(2):229-242. doi: 10.1007/s40262-017-0555-z.

PMID:
28540639
9.

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies.

Gachechiladze M, Škarda J, Soltermann A, Joerger M.

Int J Cancer. 2017 Oct 1;141(7):1286-1294. doi: 10.1002/ijc.30764. Epub 2017 May 19. Review.

PMID:
28477336
10.

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.

Parra-Guillen ZP, Berger PB, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, Gillessen S, Krähenbühl S, Kloft C, Joerger M.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):309-315. doi: 10.1111/bcpt.12801. Epub 2017 Jun 19.

PMID:
28444958
11.

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.

Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M.

J Transl Med. 2017 Mar 30;15(1):66. doi: 10.1186/s12967-017-1174-z.

12.

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.

Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK).

Invest New Drugs. 2017 Dec;35(6):766-772. doi: 10.1007/s10637-017-0454-z. Epub 2017 Mar 20.

PMID:
28317088
13.

Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients.

Gachechiladze M, Škarda J, Kolek V, Grygárková I, Langová K, Bouchal J, Kolář Z, Baty F, Stahel R, Weder W, Soltermann A, Joerger M.

Lung Cancer. 2017 Mar;105:31-38. doi: 10.1016/j.lungcan.2017.01.009. Epub 2017 Jan 18.

PMID:
28236982
14.

Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.

Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, Amstutz U, Largiader CR.

Clin Pharmacol Ther. 2017 Nov;102(5):796-804. doi: 10.1002/cpt.641. Epub 2017 May 30.

PMID:
28139840
15.

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

Meulendijks D, Rozeman EA, Cats A, Sikorska K, Joerger M, Deenen MJ, Beijnen JH, Schellens JHM.

Pharmacogenomics J. 2017 Oct;17(5):441-451. doi: 10.1038/tpj.2016.81. Epub 2016 Dec 20.

PMID:
27995989
16.

Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
.

Klopp-Schulze L, Joerger M, Wicha SG, Parra-Guillen ZP, Kloft C.

Int J Clin Pharmacol Ther. 2017 Aug;55(8):690-691. doi: 10.5414/CPXCES15EA05. No abstract available.

PMID:
27641215
17.

Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.

Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, Cerny T, Joerger M.

Lung Cancer. 2016 Oct;100:38-44. doi: 10.1016/j.lungcan.2016.07.027. Epub 2016 Jul 28.

PMID:
27597279
18.

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U.

Ann Oncol. 2016 Oct;27(10):1895-902. doi: 10.1093/annonc/mdw290. Epub 2016 Aug 8.

PMID:
27502710
19.

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

Joerger M, Finn SP, Cuffe S, Byrne AT, Gray SG.

Expert Opin Ther Targets. 2016 Nov;20(11):1339-1356. Epub 2016 Jul 11. Review.

PMID:
27353429
20.

A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction.

Warschkow R, Cerny T, Schmied BM, Güller U, Thuerlimann B, Joerger M.

Br J Cancer. 2016 Jun 28;115(1):80-4. doi: 10.1038/bjc.2016.108. Epub 2016 May 17.

21.

Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology.

Shao S, Guo T, Gross V, Lazarev A, Koh CC, Gillessen S, Joerger M, Jochum W, Aebersold R.

J Proteome Res. 2016 Jun 3;15(6):1821-9. doi: 10.1021/acs.jproteome.5b01136. Epub 2016 May 10.

PMID:
27098501
22.

Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.

Hager S, Ackermann CJ, Joerger M, Gillessen S, Omlin A.

Ann Oncol. 2016 Jun;27(6):975-84. doi: 10.1093/annonc/mdw156. Epub 2016 Apr 6. Review.

PMID:
27052650
23.

The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.

Hamzic S, Wenger N, Froehlich TK, Joerger M, Aebi S, Largiadèr CR, Amstutz U.

Pharmacogenomics J. 2017 Jul;17(4):319-324. doi: 10.1038/tpj.2016.23. Epub 2016 Mar 22.

PMID:
27001120
24.

Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis.

Warschkow R, Güller U, Tarantino I, Cerny T, Schmied BM, Thuerlimann B, Joerger M.

Ann Surg. 2016 Jun;263(6):1188-98. doi: 10.1097/SLA.0000000000001302.

PMID:
26943635
25.

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.

Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD.

Cancers (Basel). 2016 Jan 2;8(1). pii: E6. doi: 10.3390/cancers8010006.

26.

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJ.

Haematologica. 2016 Mar;101(3):346-55. doi: 10.3324/haematol.2015.135780. Epub 2015 Dec 11.

27.

Treatment regimens of classical and newer taxanes.

Joerger M.

Cancer Chemother Pharmacol. 2016 Feb;77(2):221-33. doi: 10.1007/s00280-015-2893-6. Epub 2015 Nov 20. Review.

PMID:
26589792
28.

Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry.

Shao S, Guo T, Koh CC, Gillessen S, Joerger M, Jochum W, Aebersold R.

Proteomics. 2015 Nov;15(21):3711-21. doi: 10.1002/pmic.201500161. Epub 2015 Sep 10.

PMID:
26287124
29.

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.

Kummer D, Froehlich TK, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr CR.

Pharmacogenomics. 2015;16(12):1367-77. doi: 10.2217/pgs.15.81. Epub 2015 Aug 5.

PMID:
26244261
30.

Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.

Kraff S, Lindauer A, Joerger M, Salamone SJ, Jaehde U.

Ther Drug Monit. 2015 Dec;37(6):725-32. doi: 10.1097/FTD.0000000000000206.

PMID:
25774704
31.

Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy.

Kraff S, Nieuweboer AJ, Mathijssen RH, Baty F, de Graan AJ, van Schaik RH, Jaehde U, Joerger M.

Cancer Chemother Pharmacol. 2015 May;75(5):975-83. doi: 10.1007/s00280-015-2724-9. Epub 2015 Mar 12.

PMID:
25761456
32.

Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).

Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):167-72. doi: 10.1038/pcan.2015.8. Epub 2015 Mar 10.

PMID:
25753371
33.

Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps.

Guo T, Kouvonen P, Koh CC, Gillet LC, Wolski WE, Röst HL, Rosenberger G, Collins BC, Blum LC, Gillessen S, Joerger M, Jochum W, Aebersold R.

Nat Med. 2015 Apr;21(4):407-13. doi: 10.1038/nm.3807. Epub 2015 Mar 2.

34.

Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.

Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, Sessa C.

Invest New Drugs. 2015 Apr;33(2):472-9. doi: 10.1007/s10637-015-0219-5. Epub 2015 Feb 20.

PMID:
25693886
35.

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.

Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH.

Cancer Chemother Pharmacol. 2015 Apr;75(4):763-72. doi: 10.1007/s00280-015-2698-7. Epub 2015 Feb 13.

PMID:
25677447
36.

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiadèr CR.

Clin Cancer Res. 2015 May 1;21(9):2038-44. doi: 10.1158/1078-0432.CCR-14-2817. Epub 2015 Feb 5.

37.

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C.

Br J Clin Pharmacol. 2015 Jul;80(1):128-38. doi: 10.1111/bcp.12583. Epub 2015 Jun 3.

38.

Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.

Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M.

Lung Cancer. 2015 Jan;87(1):85-7. doi: 10.1016/j.lungcan.2014.11.008. Epub 2014 Nov 18.

PMID:
25466451
39.

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.

Sistonen J, Büchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, van Kuilenburg AB, Largiadèr CR.

Pharmacogenomics. 2014 Sep;15(13):1653-66. doi: 10.2217/pgs.14.126.

PMID:
25410891
40.

Metabolism of the taxanes including nab-paclitaxel.

Joerger M.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):691-702. doi: 10.1517/17425255.2015.983074. Epub 2014 Nov 14. Review.

PMID:
25394848
41.

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).

Joerger M, Baty F, Früh M, Droege C, Stahel RA, Betticher DC, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M.

Lung Cancer. 2014 Aug;85(2):306-13. doi: 10.1016/j.lungcan.2014.04.014. Epub 2014 May 29.

PMID:
24928469
42.

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.

Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadèr CR.

Int J Cancer. 2015 Feb 1;136(3):730-9. doi: 10.1002/ijc.29025. Epub 2014 Jun 27.

43.

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.

Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thuerlimann B, Cerny T.

Eur J Clin Pharmacol. 2014 Jun;70(6):719-25. doi: 10.1007/s00228-014-1662-5. Epub 2014 Mar 11.

PMID:
24609468
44.

[Role of individualized dosing in oncology: are we there yet?].

Joerger M.

Praxis (Bern 1994). 2013 Dec 31;103(1):33-9. doi: 10.1024/1661-8157/a001516. Review. German.

PMID:
24393821
45.

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.

Joerger M, Huitema AD, Koeberle D, Rosing H, Beijnen JH, Hitz F, Cerny T, Schellens JH, Gillessen S.

Cancer Chemother Pharmacol. 2014 Jan;73(1):113-24. doi: 10.1007/s00280-013-2327-2. Epub 2013 Oct 29.

PMID:
24166106
46.

Treatment of breast cancer in the elderly: a prospective, population-based Swiss study.

Joerger M, Thürlimann B, Savidan A, Frick H, Rageth C, Lütolf U, Vlastos G, Bouchardy C, Konzelmann I, Bordoni A, Probst-Hensch N, Jundt G, Ess S.

J Geriatr Oncol. 2013 Jan;4(1):39-47. doi: 10.1016/j.jgo.2012.08.002. Epub 2012 Aug 24.

PMID:
24071491
47.

Management of elderly patients with advanced non-small cell lung cancer: a single-center experience.

Früh M, Besrour H, Gillessen S, Joerger M, Hitz F, Savidan A, Cerny T, Ess S.

Chemotherapy. 2013;59(1):42-50. doi: 10.1159/000350498. Epub 2013 Jul 2.

PMID:
23838903
48.

Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients.

Büchel B, Sistonen J, Joerger M, Aebi Y, Schürch S, Largiadèr CR.

Clin Chem Lab Med. 2013 Aug;51(8):1681-8. doi: 10.1515/cclm-2012-0641.

49.

Chemotherapy regimens in early breast cancer: major controversies and future outlook.

Joerger M, Thürlimann B.

Expert Rev Anticancer Ther. 2013 Feb;13(2):165-78. doi: 10.1586/era.12.172. Review.

PMID:
23406558
50.

Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.

Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M.

Cancer Chemother Pharmacol. 2013 Feb;71(2):361-70. doi: 10.1007/s00280-012-2018-4. Epub 2012 Nov 9.

PMID:
23139054

Supplemental Content

Loading ...
Support Center